Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Astellas Pharmaceuticals Inc. (ALPMY) and Kyowa Hakko Kirin Co., Ltd. recently announced the receipt of Japan’s Ministry of Health, Labour and Welfare (MHLW) approval for the drugs, Pasetocin and Sawacillin, for an additional indication.

The additional indication is helicobacter pylori (H. pylori) eradication by triple therapy with proton pump inhibitors and either clarithromycin or metronidazole.

We note that Astellas is also seeking label expansion for Dormicum in Japan. The company has submitted an additional indication application for “conscious sedation in dentistry and dental surgery”. Earlier, this drug was approved for three indications, namely, anesthetic premedication, introduction and maintenance of general anesthesia and sedation during artificial respiration in critical care.

A few days back, Astellas had announced final overall survival (OS) results from the phase III TIVO-1 study on tivozanib. The TIVO-1 (TIvozanib Versus sOrafenib in 1st line advanced RCC) study was conducted in patients suffering from advanced renal cell carcinoma (RCC). The company is currently seeking US Food and Drug Administration (FDA) approval for tivozanib. A New Drug Application (NDA) was submitted in Sep 2012. The FDA accepted the application in Nov 2012 with a response expected by Jul 28, 2013.

Meanwhile, Astellas is looking to expand Tarceva’s label as well. In Jan 2013, the US FDA accepted Astellas’ supplemental new drug application (sNDA) for Tarceva. Astellas is looking to expand the label of Tarceva for first-line use in patients suffering from locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) activating mutations. The FDA will review the application on a priority basis, with a response likely to be out in the second quarter of 2013. Tarceva is currently approved and marketed for maintenance therapy and second- or third-line therapy in advanced non-small cell lung cancer (NSCLC).

Astellas carries a Zacks Rank #4 (Sell). Currently, companies like Lannett Company, Inc. (LCI - Snapshot Report), SIGA Technologies, Inc. (SIGA - Snapshot Report) and United Therapeutics Corporation (UTHR - Analyst Report) look more attractive with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%